Loading contract…
BETAThis is a new independent transparency project, not an official government website. The data is sourced from public registers and may contain errors, so always verify against the official source. If you find a problem, please report it here.
NHS framework agreement to supply aseptically prepared cytotoxic medicines and monoclonal antibodies - East of England, London and South East Coast. The framework may also be used by private sector contractors and agents working on behalf of the above. The framework agreement will commence on 1.7.2020 for a period of 12 months, with options to extend for a further 36 months.
| Supplier | Identifier | Award Value | Cross-References |
|---|---|---|---|
| Baxter Healthcare Ltd | 00461365 | ~£36,000,000 estimated from lot values | LOBBYIST WA Communications Ltd (3 quarters) |
| ITH Pharma Ltd | 06569105 | ~£36,000,000 estimated from lot values | - |
| Qualasept Ltd (trading as Bath ASU) | 05548345 | ~£36,000,000 estimated from lot values | - |
Government spending data: These suppliers have received £310,032,652 in 11,639 payments (over £25k) from The Christie NHS Foundation Trust, Department of Health and Social Care, NHS Supply Chain (DHSC-funded), Guy's and St Thomas' NHS FT, Royal Cornwall Hospitals NHS Trust and 14 more public bodies (2010-04-01 to 2026-03-31).